GSK Secures Full Rights to Develop COVID-19 and Influenza Vaccines from CureVac

Jul 3, 2024, 06:30 AM

GlaxoSmithKline (GSK) has announced a new licensing agreement with CureVac, securing full rights to develop and manufacture COVID-19 and influenza vaccines. This strategic investment in vaccine platform technologies aims to enhance GSK's ability to match the best platform to each pathogen, ultimately helping to prevent illness in more people worldwide.